Document is current
Any future updates will be listed below
-
Authors
Hoobler, Rachel
Puklin, Leah S.
Harrigan, Maura
Cartmel, Brenda
Li, Fang-yong
Sanft, Tara
Ferrucci, Leah M.
Irwin, Melinda L.
Playdon, Mary C.
-
Funding
Funding for this research was provided by:
Yale Cancer Center (P30 CA016359)
National Center for Advancing Translational Sciences (UL1 TR000142)
American Institute for Cancer Research
Breast Cancer Research Foundation
National Cancer Institute (5R00CA218694-03)
Huntsman Cancer Institute, University of Utah (P30CA040214)
- License Information
-
More Information
Article History
Received: 19 July 2024
Accepted: 25 October 2024
First Online: 11 November 2024
Declarations
:
: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of Yale School of Medicine.
: Informed consent was obtained from all subjects involved in the study.
: Financial Interests: Brenda Cartmel significant other Pfizer stock. Tara Sanft paid speaker for Hologic.
: LEAN1 (NCT02109068) and LEAN2 (NCT02110641) were both pre-registered at clinicaltrials.gov. The analysis plan was not formally pre-registered.
